FDA has granted Fast Track Designation (FTD) to Perspective Therapeutics VMT01 for diagnosing and treating patients with unresectable or metastatic melanoma who have demonstrated MC1R tumor expression.
VMT01 is designed to target and deliver 212Pb to tumor sites expressing MC1R, a protein that can be overexpressed in metastatic melanoma tumors.
Perspective conducts a multi-center, open-label dose escalation, dose-expansion Phase 1/2a study for VMT01 enrolling patients with histologically confirmed melanoma and MC1R-positive imaging scans.
Dr. Markus Puhlmann, Perspective’s CMO, expressed his satisfaction with the FDA’s acknowledgment of the unmet need for additional treatment options for patients battling metastatic melanoma.
He emphasized Perspective’s commitment to collaborating closely with the FDA to accelerate the clinical development of VMT01.
Source: Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma
https://www.perspectivetherapeutics.com/newsroom/press-release?i=137680
